Current
Neuro-Oncology


Volume 24 Number 20
31 October 2022


Home > Publications > Current Neuro-Oncology > Volume 24, Year 2022 > Number 20, 31 October






Green S, Vuong VD, Khanna PC, Crawford JR.
Characterization of pediatric brain tumors using pre-diagnostic neuroimaging.
Front Oncol. 2022 Oct 17, 2022;12:977814. doi: 10.3389/fonc.2022.977814. PMID: 36324580. Observational study.




Mohamadien NRA, Diab WA, Abd El-Ghani WMA, Abdelhafez YG.
Posttherapy technetium-99m pentavalent dimercaptosuccinic acid brain single-photon emission computed tomography/computed tomography: diagnostic and prognostic values in patients with glioma.
Nucl Med Commun. 2022 Oct 17, 2022;43(12):1195-1203. doi: 10.1097/MNM.0000000000001623. PMID: 36345764. Observational study˰




Huang Y, Ding H, Luo M, Li Z, Li S, Xie C, Zhong Y.
A new approach to delineating clinical target volume for radiotherapy of glioblastoma: A phase II trial.
Front Oncol. 2022 Oct 19, 2022;12:931436. doi: 10.3389/fonc.2022.931436. PMID: 36338715. Interventional study.



*

Slavc I, Mayr L, Stepien N, Gojo J, Aliotti Lippolis M, Azizi AA, Chocholous M, Baumgartner A, Hedrich CS, Holm S, Sehested A, Leblond P, Dieckmann K, Haberler C, Czech T, Kool M, Peyrl A.
Improved Long-Term Survival of Patients with Recurrent Medulloblastoma Treated with a "MEMMAT-like" Metronomic Antiangiogenic Approach.
Cancers (Basel). 2022 Oct 19, 2022;14(20):5128. doi: 10.3390/cancers14205128. PMID: 36291912. Observational study.




Tsien CI, Pugh SL, Dicker AP, Raizer JJ, Matuszak MM, Lallana EC, Huang J, Algan O, Deb N, Portelance L, Villano JL, Hamm JT, Oh KS, Ali AN, Kim MM, Lindhorst SM, Mehta MP.
NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma.
J Clin Oncol. 2022 Oct 19, 2022:JCO2200164. doi: 10.1200/JCO.22.00164. PMID: 36260832. Interventional study˰




Veerwal H, Meena A, Dhingra V.
A Case of Extracranial Metastasis of Glioblastoma Multiforme Seen on Bone Scintigraphy.
Mol Imaging Radionucl Ther. 2022 Oct 19, 2022;31(3):246-249. doi: 10.4274/mirt.galenos.2021.09815. PMID: 36268939. Case report.



*

Liu K, Liao X, Chen Y, Jiang S.
Adjuvant Chemoradiation therapy Versus Chemotherapy Alone for Resected Oligodendroglioma: A Surveillance, Epidemiology and End Results (SEER) Analysis.
World Neurosurg. 2022 Oct 20, 2022:S1878-8750(22)01480-2. doi: 10.1016/j.wneu.2022.10.063. PMID: 36273731. Observational study.




Yang F, Dinakaran D, Heikal AA, Yaghoobpour Tari S, Ghosh S, Amanie J, Murtha A, Rowe LS, Roa W, Patel S.
Dosimetric Predictors Of Toxicity In A Randomized Study Of Short-Course Vs. Conventional Radiotherapy For Glioblastoma.
Radiother Oncol. 2022 Oct 20, 2022:S0167-8140(22)04510-8. doi: 10.1016/j.radonc.2022.10.016. PMID: 36273738. Interventional study˰




Panda PK, Gupta T, Jalali R.
A Practice Pilot Survey on the Current Use of Corticosteroid Therapy in Brain Tumor Patients.
Neurol India. 2022 Oct 21, 2022;70(5):1896-1900
. doi: 10.4103/0028-3886.359216. PMID: 36352584. Observational study.




Yang DY, Cheng X, Bu XY, Yan ZY, Qu MQ, Zhao YW, Kong LF, Wang YW, Luo JC.
Granulocyte-macrophage colony stimulating factor enhances efficacy of nimustine rendezvousing with temozolomide plus irradiation in patients with glioblastoma.
Technol Health Care. 2022 Oct 21. doi: 10.3233/THC-220194. PMID: 36314174. Observational study˰




Yi GZ, Zhu TC, Que TS, Li ZY, Huang GL.
Individualized combination therapies based on whole-exome sequencing displayed significant clinical benefits in a glioblastoma patient with secondary osteosarcoma: case report and genetic characterization.
BMC Neurol. 2022 Oct 21, 2022;22(1):390. doi: 10.1186/s12883-022-02920-x. PMID: 36271359. Case report.




Battista F, Muscas G, Dinoi F, Gadda D, Della Puppa A.
Ventricular entry during surgical resection is associated with intracranial leptomeningeal dissemination in glioblastoma patients.
J Neurooncol. 2022 Oct 23. doi: 10.1007/s11060-022-04166-6. PMID: 36273377. Observational study.




Yamaki T, Higuchi Y, Yokota H, Iwadate Y, Matsutani T, Hirono S, Sasaki H, Sasao R, Toda M, Onodera S, Oka N, Kobayashi S.
The role of optimal cut-off diagnosis in 11C-methionine PET for differentiation of intracranial brain tumor from non-neoplastic lesions before treatment.
Clin Imaging. 2022 Oct 24, 2022;92:124-130. doi: 10.1016/j.clinimag.2022.10.007. PMID: 36374712. Observational study.




Immisch L, Papafotiou G, Popp O, Mertins P, Blankenstein T, Willimsky G.
H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma.
J Immunother Cancer. 2022 Oct 27, 2022;10(10):e005535. doi: 10.1136/jitc-2022-005535. PMID: 36302563. Laboratory investigation.




Yang K, Ma Y, Chen G, Zeng S, Guo T, Yang Z.
Comparative analysis of the prognosis of external beam radiation therapy (EBRT) and EBRT plus brachytherapy for glioblastoma multiforme: a SEER population-based study.
Radiat Oncol. 2022 Oct 28, 2022;17(1):174. doi: 10.1186/s13014-022-02141-z. PMID: 36307810. Observational study.




Rudà R, Bruno F, Pellerino A, Pronello E, Palmiero R, Bertero L, Crasto S, Polo V, Vitaliani R, Trincia E, Internò V, Porta C, Soffietti R.
Observational real-life study on regorafenib in recurrent glioblastoma: does dose reduction reduce toxicity while maintaining the efficacy?
J Neurooncol. 2022 Oct 30. doi: 10.1007/s11060-022-04155-9. PMID: 36309895. Observational study˰




Șerban G, Tămaș F, Bălașa R, Manu D, Tămaș C, Bălașa A.
Prognostic Factors of Survival in Glioblastoma Multiforme Patients-A Retrospective Study.
Diagnostics (Basel). 2022 Oct 30, 2022;12(11):2630. doi: 10.3390/diagnostics12112630. PMID: 36359474. Observational study.




Greenwell AM, Baughan S, Altinok D, Marupudi NI, Kupsky W, Kumar-Sinha C, Gorsi HS.
Lorlatinib for the Treatment of ALK Fusion-Positive Infant-Type Hemispheric Glioma: A Case Report.
JCO Precis Oncol. 2022 Oct 31, 2022;6:e2200255. doi: 10.1200/PO.22.00255. PMID: 36315913. Case report˰